Affin Hwang Investment Bank has retained its 'Hold' rating on UMediC Group Bhd, citing muted earnings growth momentum despite the company meeting expectations for the first nine months of the year.
The broker noted that UMediC's nine-month earnings accounted for 71 per cent of its full-year forecast, indicating that the company is broadly on track to meet its annual targets.
However, the lack of significant upside surprise has led Affin Hwang to maintain a cautious stance on the stock.
UMediC, a key player in Malaysia's healthcare sector, continues to face a challenging environment where steady execution is rewarded but rapid growth remains elusive.
The broker's assessment suggests that while the company's fundamentals are stable, there is limited catalyst for a re-rating in the near term.
Investors in Malaysian healthcare equities are likely to monitor UMediC's full-year results for any signs of acceleration.